Hepatitis C virus elimination: laying the foundation for achieving 2030 targets

doi:10.1038/s41575-020-00392-3

Review

. 2021 Feb;18(2):91-92.

doi: 10.1038/s41575-020-00392-3.

Hepatitis C virus elimination: laying the foundation for achieving 2030 targets

Gregory J Dore¹, Sahar Bajis²

Affiliations

¹ Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. gdore@kirby.unsw.edu.au.
² Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

PMID: 33257831
PMCID: PMC7702726
DOI: 10.1038/s41575-020-00392-3

Review

Hepatitis C virus elimination: laying the foundation for achieving 2030 targets

Gregory J Dore et al. Nat Rev Gastroenterol Hepatol. 2021 Feb.

. 2021 Feb;18(2):91-92.

doi: 10.1038/s41575-020-00392-3.

Authors

Gregory J Dore¹, Sahar Bajis²

Affiliations

¹ Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia. gdore@kirby.unsw.edu.au.
² Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia.

PMID: 33257831
PMCID: PMC7702726
DOI: 10.1038/s41575-020-00392-3

Erratum in

Author Correction: Hepatitis C virus elimination: laying the foundation for achieving 2030 targets.
Dore GJ, Bajis S. Dore GJ, et al. Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):143. doi: 10.1038/s41575-020-00407-z. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33402712 Free PMC article. No abstract available.

Abstract

The World Health Organization’s targets for hepatitis C elimination by 2030 are ambitious, but, in 2020, global leadership demonstrated by Egypt, innovative strategies to improve linkage to treatment for marginalized populations and the broadened capacity of direct-acting antiviral therapy have been promising for enhanced global elimination efforts.

PubMed Disclaimer

Conflict of interest statement

G.J.D. is an advisory board member and receives honorarium from Gilead, Merck and Abbvie, has received research grant funding from Gilead, Merck and Abbvie, and travel sponsorship from Gilead, Merck and Abbvie. S.B. declares no competing interests.

Figures

**Fig. 1. Cascade of HCV care in Egypt.**
Oct 2018–Sep 2019. HCV, hepatitis C virus. Data from ref..

See this image and copyright information in PMC

Cited by

Development and Validation of a Questionnaire to Measure Medication Adherence to Direct-Acting Agents in Patients with Hepatitis C.
Turcu-Stiolica A, Doica IP, Ungureanu BS, Rogoveanu I, Florescu DN, Subtirelu MS, Gheonea DI. Turcu-Stiolica A, et al. Pharmaceutics. 2021 Oct 14;13(10):1683. doi: 10.3390/pharmaceutics13101683. Pharmaceutics. 2021. PMID: 34683976 Free PMC article.
Country versus pharmaceutical company interests for hepatitis C treatment.
Lothan R, Gutman N, Yamin D. Lothan R, et al. Health Care Manag Sci. 2022 Dec;25(4):725-749. doi: 10.1007/s10729-022-09607-2. Epub 2022 Aug 24. Health Care Manag Sci. 2022. PMID: 36001218 Free PMC article.
Polyvalent immunization elicits a synergistic broadly neutralizing immune response to hypervariable region 1 variants of hepatitis C virus.
Mosa AI, Campo DS, Khudyakov Y, AbouHaidar MG, Gehring AJ, Zahoor A, Ball JK, Urbanowicz RA, Feld JJ. Mosa AI, et al. Proc Natl Acad Sci U S A. 2023 Jun 13;120(24):e2220294120. doi: 10.1073/pnas.2220294120. Epub 2023 Jun 5. Proc Natl Acad Sci U S A. 2023. PMID: 37276424 Free PMC article.
Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies.
Khalsa JH, Mathur P. Khalsa JH, et al. Viruses. 2021 Jul 14;13(7):1363. doi: 10.3390/v13071363. Viruses. 2021. PMID: 34372569 Free PMC article. Review.
HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation.
Work HM, Hackett JC, Lampe JN. Work HM, et al. Drug Metab Dispos. 2024 May 16;52(6):516-525. doi: 10.1124/dmd.123.001434. Drug Metab Dispos. 2024. PMID: 38267095 Free PMC article.

See all "Cited by" articles

References

1. Choo QL, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362. doi: 10.1126/science.2523562. - DOI - PubMed
1. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-... (WHO, 2016).
1. Naghavi M, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210. doi: 10.1016/S0140-6736(17)32152-9. - DOI - PMC - PubMed
1. World Health Organization. Global Hepatitis Report, 2017https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-en... (WHO, 2017).
1. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin. Infect. Dis. 2015;60:1829–1836. doi: 10.1093/cid/civ197. - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] Choo QL, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362. doi: 10.1126/science.2523562. - DOI - PubMed

[2] Choo QL, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362. doi: 10.1126/science.2523562. - DOI - PubMed

[3] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-... (WHO, 2016).

[4] World Health Organization. Global health sector strategy on viral hepatitis 2016-2021https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-... (WHO, 2016).

[5] Naghavi M, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210. doi: 10.1016/S0140-6736(17)32152-9. - DOI - PMC - PubMed

[6] Naghavi M, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210. doi: 10.1016/S0140-6736(17)32152-9. - DOI - PMC - PubMed

[7] World Health Organization. Global Hepatitis Report, 2017https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-en... (WHO, 2017).

[8] World Health Organization. Global Hepatitis Report, 2017https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-en... (WHO, 2017).

[9] Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin. Infect. Dis. 2015;60:1829–1836. doi: 10.1093/cid/civ197. - DOI - PubMed

[10] Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin. Infect. Dis. 2015;60:1829–1836. doi: 10.1093/cid/civ197. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Hepatitis C virus elimination: laying the foundation for achieving 2030 targets

Affiliations

Hepatitis C virus elimination: laying the foundation for achieving 2030 targets

Authors

Affiliations

Erratum in

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Erratum in

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical